These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25692408)

  • 1. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
    Brady SW; Zhang J; Tsai MH; Yu D
    Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS; Arnold SL; O'Regan RM; Nahta R
    Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
    Brady SW; Zhang J; Seok D; Wang H; Yu D
    Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y; Yashiro M; Takakura N
    Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
    Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
    J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
    Zervantonakis IK; Poskus MD; Scott AL; Selfors LM; Lin JR; Dillon DA; Pathania S; Sorger PK; Mills GB; Brugge JS
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16500-16508. PubMed ID: 32601199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
    Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
    Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
    Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
    Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
    Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
    Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
    [No Abstract]   [Full Text] [Related]  

  • 19. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
    Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
    Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.